Pipeline Insight: Insulins - Inhalable insulins unlikely to become blockbusters

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2006-09-14

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Datamonitor expects the continuously growing prevalence of diabetes to drive growth in diabetes drug spending, potentially benefiting market uptake of novel insulin therapies. A set of novel, non-injectable insulins are poised to become available to patients in the next five years. By 2010, the market will thus have to absorb Pfizer's Exubera and at least three other inhalable insulins.


Scope

  • Assessment of the patient potential for developmental insulin therapy over the period 2006 to 2015
  • Overview of the insulin pipeline, with detailed information on the insulins in development and injectable comparators as well as market entry barriers
  • Commercial analysis of key insulin products in development regarding their ability to satisfy unmet needs, supported by the views of opinion leaders
  • Sales forecasts for four key inhalable insulin preparations in the seven major markets to 2015


    • Report Highlights
    The diabetes market is worthy of investment because of the endemic size of its patient pool which is set to grow further. However, the efficacy of marketed injectable insulins is difficult to improve upon and this is reflected in the R&D pipeline for insulins, comprising a small set of only 17 novel insulin products in clinical development.

    Datamonitor has identified three late-stage insulins likely to be launched into the diabetes market within the next five years. These are the inhalable formulations AERx-iDMS, AIR and Technosphere all of which may coexist with Exubera because their technical diversity is likely to cater for a wide spectrum of patient needs and preference.

    The diabetes market will not be receptive to inhalable insulins until compelling data are generated that demonstrate compelling clinical benefits of inhalable insulins over injectables. This view is supported by the recent cost-benefit analyses of it by Germany's IQWiG and UK's NICE, and the distinct lack of opinion leader enthusiasm about Exubera.


    Reasons to Purchase

  • Explore the key factors that will contribute to the success of the next generation of insulins
  • View independent sales forecasts for products in late stage development for insulin-based diabetes therapy
  • Understand physician opinions of non-injectable insulins and unmet needs in the diabetes market

    • Table of Contents

    Other users found this report page using the following search terms: insulin drug delivery inhalable exubera phase insulin diabetes insulins inhalable pipeline analysis novo future swot

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.